Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 18/20 | 0.74 |
| ▸ | PTGER1 | P34995 | 9/20 | 0.74 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.74 |
| ▸ | SLCO2A1 | Q92959 | 1/20 | 0.65 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7124363 | 1.00 | PTGFR (0.74) | PTGFRPTGER1PTGER2SLCO2A1PTGER3 | |
| SCHEMBL11314061 | 0.88 | PTGFR (0.58) | PTGFRPTGER1PTGER2SLCO2A1PTGER3 | |
| SCHEMBL11314066 | 0.88 | PTGFR (0.58) | PTGFRPTGER1PTGER2SLCO2A1PTGER3 | |
| SCHEMBL11314064 | 0.88 | PTGFR (0.58) | PTGFRPTGER1PTGER2SLCO2A1PTGER3 | |
| SCHEMBL22580499 | 0.85 | PTGFR (1.00) | PTGFRPTGER1PTGER2SLCO2A1PTGER3 | |
| SCHEMBL24226152 | 0.85 | PTGFR (0.67) | PTGFRPTGER1PTGER2SLCO2A1PTGER3 | |
| SCHEMBL14627145 | 0.85 | PTGFR (0.67) | PTGFRPTGER1PTGER2SLCO2A1PTGER3 | |
| SCHEMBL19152027 | 0.84 | PTGFR (0.66) | PTGFRPTGER1PTGER2SLCO2A1PTGER3 | |
| SCHEMBL18939648 | 0.84 | PTGFR (0.66) | PTGFRPTGER1PTGER2SLCO2A1PTGER3 | |
| SCHEMBL23975177 | 0.84 | PTGFR (0.66) | PTGFRPTGER1PTGER2SLCO2A1PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187071-A1 | Process and intermediates to prepare latanoprost | PHARMACIA & UPJOHN COMPANY | 2003-10-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187071-A1 | Process and intermediates to prepare latanoprost | CYP1B1, CYP26B1, CYP26A1 | PTGFR 46/4885PTGER1 6/4885PTGER2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.